Evidence map›Paper›PMID 36201206›Full record

ArticleJAMA otolaryngology-- head & neck surgery2022

Assessment of BMI and Venous Thromboembolism Rates in Patients on Standard Chemoprophylaxis Regimens After Undergoing Free Tissue Transfer to the Head and Neck.

Rakan Saadoun, Fuat Baris Bengur, Elizabeth A Moroni, Yusuf Surucu, Johannes A Veit, Nayel I Khan, Kelly Daniels, Scott D Rothenberger, Mark Kubik, Mario G Solari and 1 more

Open access · greenAbstract read
In one paragraph

Article in JAMA otolaryngology-- head & neck surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Rakan SaadounDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Fuat Baris BengurDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Elizabeth A MoroniDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Yusuf SurucuDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Johannes A VeitDepartment of Otorhinolaryngology-Head and Neck Surgery, University Medical Centre Mannheim, Mannheim, Germany.
Nayel I KhanDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Kelly DanielsDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Scott D RothenbergerDivision of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Mark KubikDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Mario G SolariDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Shaum SridharanDepartment of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
University of Pittsburgh · USUniversity of Pittsburgh Medical Center · USHeidelberg University · DEUniversity Medical Centre Mannheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Venous thromboembolism (VTE) is a severe complication after free tissue transfer to the head and neck (H&N). Enoxaparin 30 mg twice daily (BID) is a common regimen for chemoprophylaxis. However, differences in enoxaparin metabolism based on body weight may influence its efficacy and safety profile. Objective: To assess the association between BMI and postoperative VTE and hematoma rates in patients treated with prophylactic enoxaparin 30 mg BID. Design, Setting, and Participants: This was a retrospective review of a prospectively collected cohort from 2012 to 2022. Postoperative VTE, hematoma, and free flap pedicle thrombosis were recorded within 30 days of index surgery. The setting was a tertiary academic referral center. Participants included patients undergoing H&N reconstruction with free flaps that received fixed-dose subcutaneous enoxaparin 30 mg BID postoperatively. Statistical analysis was conducted from April to May 2022. Main Outcomes and Measures: Outcomes include incidence of VTE, hematoma, and flap pedicle thrombosis events within 30 days of the surgery. Univariate and multivariable regression models were used to evaluate associations between BMI and other patient factors with these outcomes. Results: Among the 765 patients included, 262 (34.24%) were female; mean (SD) age was 60.85 (12.64) years; and mean (SD) BMI was 26.36 (6.29). The rates of VTE and hematoma in the cohort were 3.92% (30 patients) and 5.09% (39 patients), respectively. After adjusting for patient factors, BMI was the only factor associated with VTE (OR, 1.07; 95% CI, 1.015-1.129). Obesity (BMI >30) was associated with increased odds of VTE (OR, 2.782; 95% CI, 1.197-6.564). Hematoma was not associated with BMI (OR, 0.988; 95% CI, 0.937-1.041). Caprini score of at least 9 was not associated with VTE (OR, 1.259; 95% CI, 0.428-3.701). Conclusions and Relevance: This cohort study found that obesity was associated with an increased risk of VTE in patients after microvascular H&N reconstruction and while on standard postoperative chemoprophylaxis regimens. This association may suggest insufficient VTE prophylaxis in this group and a potential indication for weight-based dosing.

Indexed as

ThrombosisVenous ThromboembolismAnticoagulantsBody Mass IndexChemopreventionCohort StudiesEnoxaparinFemaleHumansMaleMiddle AgedObesityPostoperative ComplicationsRetrospective StudiesAnticoagulantsEnoxaparin

Identifiers

PMID36201206
PMCPMC9539733
OpenAlexW4302307024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.